Explore the latest in targeted and immune therapies, including recent advances in precision therapies and in use of tumor checkpoint inhibitors.
This meta-analysis assesses the overall treatment outcome associated with ICIs compared with standard therapies in patients with unresectable hepatocellular carcinoma.
This cohort study examines whether cancer immunotherapy effectiveness varies between female and male patients with advanced melanoma treated with either nivolumab plus ipilimumab combination therapy or anti–programmed cell death protein 1 therapy.
This narrative review discusses recent advances in use of combination therapy for patients with metastatic clear cell renal cell carcinoma.
This cohort study examines the ability of patients receiving chimeric antigen receptor T-cell treatments to mount T-cell immunity in response to messenger RNA vaccines for severe acute respiratory syndrome coronavirus 2 despite substantial B-cell depletion.
This comparative effectiveness study examines atezolizumab, nivolumab, and docetaxel in patients with advanced non–small cell lung cancer (NSCLC) resistant to platinum-based chemotherapy.
This economic evaluation assesses the cost-effectiveness of atezolizumab and vemurafenib plus cobimetinib in patients with metastatic melanoma from the US health care perspective
This cross-sectional study evaluates the representation of racial and ethnic minority groups in breast, prostate, lung, and colorectal cancer studies with a focus on precision medicine objectives.
This cohort study examines immune checkpoint inhibitor use and survival outcomes among patients with advanced cancers who are traditionally trial ineligible based on poor performance status or organ dysfunction.
This cohort study examines clinical outcomes and safety of immune checkpoint inhibitors among geriatric patients with cancer.
This cross-sectional study examines atezolizumab as a second-line treatment for malignant urothelial carcinoma, which received accelerated US Food and Drug Administration approval, although the manufacturer’s confirmatory trial did not identify benefits.
This cohort study examines the association of liver biopsy with management and outcomes of high-grade immune checkpoint inhibitor hepatitis.
This randomized clinical trial compares ensartinib with crizotinib among patients with advanced anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) who had not received prior treatment with an ALK inhibitor.
This narrative review provides an overview of the diagnostic and therapeutic approach for patients with suspected immune checkpoint inhibitor–associated myocarditis.
This Viewpoint discusses trials of immunotherapy for the treatment of small-cell lung cancer.
This systematic review examines the development of subtypes of cutaneous immune-related adverse events in patients receiving immune checkpoint inhibitors and provide recommendations on optimal treatment regimens based on the current literature.
This JAMA Oncology Patient Page explains the adverse effects that can result from immunotherapy treatment in patients with cancer.
A 65-year-old woman with locally advanced, unresectable intrahepatic cholangiocarcinoma and receiving pemigatinib therapy presented with a painful eruption on the bilateral lower extremities. What is your diagnosis?
Customize your JAMA Network experience by selecting one or more topics from the list below.